


Dabrafenib + trametinib COMBI-d

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Not qualified for an ESMO-MCBS credit



Serious and disabling adverse effects



Improved toxicity profile



Other adjustments



Dabrafenib + trametinib COMBI-d

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Skin Cancers

Therapeutic Indication: Dabrafenib in combination with trametinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation

Experimental Arm: Dabrafenib + trametinib

Control Arm: Dabrafenib

